UPDATE 1-Allergan CEO, fresh off one deal, sets sights on others
July 27, 2015 at 17:12 PM EDT
NEW YORK, July 27 (Reuters) - Allergan plc CEO Brent Saunders is ready to put the $36 billion his company will net from the sale of its generics business to Teva Pharmaceutical Industries Ltd to work, possibly with another large, "transformational" merger.